Acadian Asset Management LLC Purchases New Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Acadian Asset Management LLC acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 6,884 shares of the biopharmaceutical company’s stock, valued at approximately $111,000.

Several other institutional investors have also added to or reduced their stakes in ACAD. Norges Bank bought a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at $45,187,000. Eventide Asset Management LLC bought a new position in ACADIA Pharmaceuticals during the 4th quarter valued at about $25,342,000. M&G Plc purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter valued at about $5,622,000. WCM Investment Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter valued at about $5,215,000. Finally, Jupiter Asset Management Ltd. grew its stake in shares of ACADIA Pharmaceuticals by 21.3% in the first quarter. Jupiter Asset Management Ltd. now owns 1,603,774 shares of the biopharmaceutical company’s stock worth $29,654,000 after acquiring an additional 281,410 shares during the period. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, CEO Stephen Davis sold 31,747 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $485,094.16. Following the completion of the transaction, the chief executive officer now owns 186,555 shares of the company’s stock, valued at $2,850,560.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Stephen Davis sold 31,747 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $485,094.16. Following the transaction, the chief executive officer now owns 186,555 shares of the company’s stock, valued at $2,850,560.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Brendan Teehan sold 9,534 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares of the company’s stock, valued at approximately $797,264.56. The disclosure for this sale can be found here. Insiders have sold a total of 51,014 shares of company stock valued at $779,494 over the last ninety days. 28.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald dropped their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. Needham & Company LLC dropped their price target on ACADIA Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. Royal Bank of Canada reduced their price objective on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. BMO Capital Markets began coverage on ACADIA Pharmaceuticals in a report on Thursday, June 27th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, Morgan Stanley downgraded ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $28.00 to $20.00 in a research note on Wednesday, August 7th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $25.56.

ACADIA Pharmaceuticals Trading Up 0.7 %

ACADIA Pharmaceuticals stock opened at $16.53 on Friday. ACADIA Pharmaceuticals Inc. has a 12-month low of $14.55 and a 12-month high of $32.59. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -1,653.00, a P/E/G ratio of 0.53 and a beta of 0.40. The firm has a 50 day moving average of $16.81 and a 200 day moving average of $16.83.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. ACADIA Pharmaceuticals had a net margin of 3.43% and a return on equity of 6.89%. The firm had revenue of $241.96 million during the quarter, compared to analysts’ expectations of $235.95 million. During the same period in the prior year, the company posted $0.01 earnings per share. The company’s revenue for the quarter was up 46.4% compared to the same quarter last year. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.52 EPS for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.